However, the KRAS gene is frequently mutated in a variety of human cancers, especially non–small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma (PDAC), resulting in the oncogenic activation of the KRAS protein (2, 3). This evidence concerns the gene KRAS and lung cancer.